Recent Analysts’ Ratings Changes for OrthoPediatrics (KIDS)

A number of research firms have changed their ratings and price targets for OrthoPediatrics (NASDAQ: KIDS):

  • 11/3/2026 – OrthoPediatrics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 10/28/2026 – OrthoPediatrics had its price target raised by Lake Street Capital from $34.00 to $38.00. They now have a “buy” rating on the stock.
  • 10/28/2026 – OrthoPediatrics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $30.00 price target on the stock, up from $25.00.
  • 10/28/2026 – OrthoPediatrics had its price target raised by Canaccord Genuity Group from $28.00 to $30.00. They now have a “buy” rating on the stock.
  • 10/28/2026 – OrthoPediatrics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $35.00 price target on the stock.
  • 10/28/2026 – OrthoPediatrics had its price target raised by TD Cowen from $23.00 to $28.00. They now have a “buy” rating on the stock.
  • 10/28/2026 – OrthoPediatrics had its price target raised by BTIG Research from $29.00 to $30.00. They now have a “buy” rating on the stock.
  • 10/28/2026 – OrthoPediatrics had its price target raised by Stifel Nicolaus from $24.00 to $27.00. They now have a “buy” rating on the stock.
  • 10/28/2026 – OrthoPediatrics had its price target raised by Truist Financial from $22.00 to $28.00. They now have a “hold” rating on the stock.
  • 10/1/2026 – OrthoPediatrics was upgraded by Truist Financial to “hold”.

OrthoPediatrics Stock Down 0.3%

KIDS stock traded down $0.10 during midday trading on Tuesday, reaching $31.39. 91,628 shares of the company’s stock traded hands, compared to its average volume of 200,289. The company has a market cap of $819.72 million, a price-to-earnings ratio of -21.95 and a beta of 0.90. The firm’s fifty day moving average price is $25.25 and its 200-day moving average price is $20.37. OrthoPediatrics Corp. has a 52 week low of $14.42 and a 52 week high of $34.53. The company has a quick ratio of 2.00, a current ratio of 4.55 and a debt-to-equity ratio of 0.29.

OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.02). OrthoPediatrics had a negative net margin of 12.83% and a negative return on equity of 8.10%. The company had revenue of $72.66 million for the quarter, compared to the consensus estimate of $68.50 million. As a group, sell-side analysts forecast that OrthoPediatrics Corp. will post -1.09 earnings per share for the current fiscal year.

Insider Activity at OrthoPediatrics

In other OrthoPediatrics news, Director David Pelizzon sold 302,369 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the sale, the director directly owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. This represents a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Jennifer Pritzker sold 302,369 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the transaction, the insider owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. This represents a 4.65% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 2,100,000 shares of company stock worth $46,747,931. Company insiders own 32.50% of the company’s stock.

OrthoPediatrics Corp. develops and markets orthopedic implants and instruments designed specifically for children and adolescents. Its products support surgeons treating a range of pediatric conditions, including fractures, spinal deformities, limb-length differences and other orthopedic disorders. The company’s portfolio includes systems for trauma and deformity correction, scoliosis treatment, limb lengthening and external fixation, as well as specialized surgical instruments. It also provides related education and support for pediatric orthopedic surgeons and care teams.

Read More

Receive News & Ratings for OrthoPediatrics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics Corp and related companies with MarketBeat.com's FREE daily email newsletter.